Midazolam (Versed, Dormicum)

Other Medications · Approved since 1985

FDA Approved

EMA Approved

Hospital use other indication IV, Oral, Intramuscular 6 Clinical Trials

GABA-A receptors

Description

Midazolam is a short-acting benzodiazepine medication used as supportive care in colorectal cancer treatment settings. It serves primarily as a sedative and anxiolytic agent during procedures, diagnostic imaging, or to manage anxiety and agitation in cancer patients. In the context of CRC clinical trials, midazolam may be administered as premedication or procedural sedation during treatment protocols or research procedures.

Mechanism of Action

Midazolam enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors in the central nervous system. This potentiation of inhibitory neurotransmission results in sedative, anxiolytic, muscle relaxant, and anticonvulsant effects through increased chloride ion influx and neuronal hyperpolarization.

Molecular Targets

GABA-A receptors

Side Effects

Drowsiness Confusion Memory impairment Respiratory depression Hypotension Dizziness Headache Nausea

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06835569 Phase 1

Recruiting

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

United States

NCT05355701 Phase 1

Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

United States, Canada, Israel

NCT04973163 Phase 1

Active, not recruiting

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

United States, Belgium, Spain, United Kingdom

NCT04557449 Phase 2

Active, not recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

United States, Argentina, China, Czechia, Japan, Mexico, Slovakia, United Kingdo

NCT03600883 Phase 1

Completed

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

United States, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Gre

NCT02857270 Phase 1

Archived

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

United States, Australia, France, Japan

Quick Info

Brand Name	Versed, Dormicum
Category	Other Medications
Status	FDA Approved
EMA Status	EMA Approved
Spain Access	Hospital use other indication
Administration	IV, Oral, Intramuscular
Year Approved	1985
Clinical Trials	6

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.